Experimental cancer therapy tested in just one patient
NCT ID NCT07123493
First seen Nov 18, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This early-phase trial tested a new cell therapy for people with advanced solid tumors that have a specific marker called ALPP. The treatment uses the patient's own immune cells, modified to attack the cancer. Only one person took part before the study was stopped early, and the main goal was to check safety and find the right dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC SOLID TUMORS WITH POSITIVE ALPP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
Conditions
Explore the condition pages connected to this study.